MedTrace Logo

Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis

NCT07093268 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-07-30

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and tolerability of intrathecal riluzole in adults with amyotrophic lateral sclerosis.

Conditions

Interventions

DRUG

Intrathecal Riluzole

Intrathecal infusion of riluzole for 6 weeks followed by 6 months treatment with safety committee approval.

Sponsors & Collaborators

  • Brain Trust Bio

    lead INDUSTRY

Principal Investigators

  • David Schultz, Dr · Flinders Medical Centre

  • Antony Winkel, Dr · Sunshine Coast University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-15
Primary Completion
2026-06-15
Completion
2027-01-15

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07093268 on ClinicalTrials.gov